PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

Epithelial-Mesenchymal Transition in Non Small-cell Lung Cancer.

Abstract Lung cancer is the first cause of cancer related deaths in both males and females. Epithelial-mesenchymal transition (EMT) is a reversible process by which epithelial cells transform to mesenchymal stem cells by losing their cell polarity and cell-to-cell adhesion, gaining migratory and invasive properties. High levels of E-cadherin are expressed in epithelial cells, whereas mesenchymal cells express high levels of N-cadherin, fibronectin and vimentin. The aim of this study was to evaluate the correlation between E-cadherin and vimentin expression and their clinical significance in non-small cell lung cancer (NSCLC).
PMID
Related Publications

Epithelial-to-mesenchymal transition in the development and progression of adenocarcinoma and squamous cell carcinoma of the lung.

Comparison of epithelial-mesenchymal transition-related markers between cancer tissue and tumor emboli.

Epithelial-mesenchymal transition in patients of pulmonary adenocarcinoma: correlation with cancer stem cell markers and prognosis.

Twist may be associated with invasion and metastasis of hypoxic NSCLC cells.

Clinicopathological significance of KAI1 expression and epithelial-mesenchymal transition in non-small cell lung cancer.

Authors

Mayor MeshTerms

Epithelial-Mesenchymal Transition

Keywords

E-Cadherin

biomarker

epithelial mesenchymal transition (EMT)

non-small-cell lung cancer (NSCLC)

prognosis

vimentin

Journal Title anticancer research
Publication Year Start




PMID- 28373440
OWN - NLM
STAT- MEDLINE
DA  - 20170404
DCOM- 20170413
LR  - 20170413
IS  - 1791-7530 (Electronic)
IS  - 0250-7005 (Linking)
VI  - 37
IP  - 4
DP  - 2017 Apr
TI  - Epithelial-Mesenchymal Transition in Non Small-cell Lung Cancer.
PG  - 1773-1778
AB  - BACKGROUND/AIM: Lung cancer is the first cause of cancer related deaths in both
      males and females. Epithelial-mesenchymal transition (EMT) is a reversible
      process by which epithelial cells transform to mesenchymal stem cells by losing
      their cell polarity and cell-to-cell adhesion, gaining migratory and invasive
      properties. High levels of E-cadherin are expressed in epithelial cells, whereas 
      mesenchymal cells express high levels of N-cadherin, fibronectin and vimentin.
      The aim of this study was to evaluate the correlation between E-cadherin and
      vimentin expression and their clinical significance in non-small cell lung cancer
      (NSCLC). MATERIALS AND METHODS: The immunohistochemical expression of E-cadherin,
      vimentin and Ki-67 was performed on tissue microarrays from NSCLC specimens
      obtained from 112 newly- diagnosed cases and were studied using classical
      pathological evaluation. Associations between E-cadherin, vimentin and Ki-67
      expression, clinicopathological variables and survival were analyzed. In all
      cases, a value of p</=0.05 was considered significant. RESULTS: Low E-cadherin
      expression was significantly correlated with tumor necrosis (p=0.019). Moreover, 
      there was a trend for correlation between high E-cadherin expression and better
      overall survival (hazard ratio=1.02, and 95% confidence interval=0.45-1.87,
      p=0.091). There was also a significant negative correlation between vimentin
      expression and overall survival (hazard ratio=1.13, and 95% confidence
      interval=0.78-1.65, p=0.026). Additionally, there was a significant negative
      correlation between vimentin expression and grade I tumors (p=0.031). Finally, a 
      positive correlation trend between vimentin expression and Ki-67 was found
      (p=0.073). CONCLUSION: High E-cadherin and low vimentin expression correlate with
      better prognosis and overall survival.
CI  - Copyright(c) 2017, International Institute of Anticancer Research (Dr. George J. 
      Delinasios), All rights reserved.
FAU - Tsoukalas, Nikolaos
AU  - Tsoukalas N
AD  - Department of Oncology, Veterans Hospital (NIMTS), Athens, Greece
      [email protected]
FAU - Aravantinou-Fatorou, Eleni
AU  - Aravantinou-Fatorou E
AD  - 251 Air Force Hospital, Athens, Greece.
FAU - Tolia, Maria
AU  - Tolia M
AD  - Department of Radiotherapy-Radiation Oncology, Faculty of Medicine, School of
      Health Sciences, University of Thessaly, Larissa, Greece.
FAU - Giaginis, Constantinos
AU  - Giaginis C
AD  - First Department of Pathology, Medical School, University of Athens, Athens,
      Greece.
FAU - Galanopoulos, Michail
AU  - Galanopoulos M
AD  - 401 General Military Hospital, Athens, Greece.
FAU - Kiakou, Maria
AU  - Kiakou M
AD  - 401 General Military Hospital, Athens, Greece.
FAU - Kostakis, Ioannis D
AU  - Kostakis ID
AD  - 401 General Military Hospital, Athens, Greece.
FAU - Dana, Eugene
AU  - Dana E
AD  - First Department of Pathology, Medical School, University of Athens, Athens,
      Greece.
FAU - Vamvakaris, Ioannis
AU  - Vamvakaris I
AD  - First Department of Pathology, Medical School, University of Athens, Athens,
      Greece.
FAU - Korogiannos, Athanasios
AU  - Korogiannos A
AD  - First Department of Pathology, Medical School, University of Athens, Athens,
      Greece.
FAU - Tsiambas, Evangelos
AU  - Tsiambas E
AD  - 401 General Military Hospital, Athens, Greece.
FAU - Salemis, Nikolaos
AU  - Salemis N
AD  - 401 General Military Hospital, Athens, Greece.
FAU - Kyrgias, George
AU  - Kyrgias G
AD  - Department of Radiotherapy-Radiation Oncology, Faculty of Medicine, School of
      Health Sciences, University of Thessaly, Larissa, Greece.
FAU - Karameris, Andreas
AU  - Karameris A
AD  - Department of Pathology, Veterans Hospital (NIMTS), Athens, Greece.
FAU - Theocharis, Stamatios
AU  - Theocharis S
AD  - First Department of Pathology, Medical School, University of Athens, Athens,
      Greece.
LA  - eng
PT  - Journal Article
PL  - Greece
TA  - Anticancer Res
JT  - Anticancer research
JID - 8102988
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (CDH1 protein, human)
RN  - 0 (Cadherins)
RN  - 0 (FN1 protein, human)
RN  - 0 (Fibronectins)
RN  - 0 (Vimentin)
SB  - IM
MH  - Adenocarcinoma/metabolism/*pathology
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Biomarkers, Tumor/*metabolism
MH  - Cadherins/metabolism
MH  - Carcinoma, Large Cell/metabolism/*pathology
MH  - Carcinoma, Non-Small-Cell Lung/metabolism/*pathology
MH  - Carcinoma, Squamous Cell/metabolism/*pathology
MH  - *Epithelial-Mesenchymal Transition
MH  - Female
MH  - Fibronectins/metabolism
MH  - Follow-Up Studies
MH  - Humans
MH  - Immunoenzyme Techniques
MH  - Lung Neoplasms/metabolism/*pathology
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Invasiveness
MH  - Neoplasm Staging
MH  - Prognosis
MH  - Survival Rate
MH  - Tissue Array Analysis
MH  - Vimentin/metabolism
OTO - NOTNLM
OT  - *E-Cadherin
OT  - *biomarker
OT  - *epithelial mesenchymal transition (EMT)
OT  - *non-small-cell lung cancer (NSCLC)
OT  - *prognosis
OT  - *vimentin
EDAT- 2017/04/05 06:00
MHDA- 2017/04/14 06:00
CRDT- 2017/04/05 06:00
PHST- 2017/02/16 [received]
PHST- 2017/03/20 [revised]
PHST- 2017/03/21 [accepted]
AID - 37/4/1773 [pii]
AID - 10.21873/anticanres.11510 [doi]
PST - ppublish
SO  - Anticancer Res. 2017 Apr;37(4):1773-1778.

<?xml version="1.0" encoding="UTF-8"?>
<b:Sources SelectedStyle="" xmlns:b="http://schemas.openxmlformats.org/officeDocument/2006/bibliography"  xmlns="http://schemas.openxmlformats.org/officeDocument/2006/bibliography" >
</b:Sources>